3 results
Approved WMOPending
to evaluate the safety and efficacy of ECP as adjunct first-line therapy in patients with newly diagnosed chronic GVHD of the liver or lungs
Approved WMOCompleted
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
Approved WMORecruiting
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)